Powerful, cost-effective system to provide highest accuracy sequencing data for range of applications

CARLSBAD, Calif.–Life Technologies Corporation (NASDAQ: LIFE) today announced plans for the Applied Biosystems SOLiD™ PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.

“As sequencing becomes an ever more important tool for scientists to unlock the mechanisms of disease, it is critical that we provide a range of system solutions that meet the unique requirements of individual researchers”

The SOLiD PI System, designed in partnership with Hitachi High-Technologies Corporation, will provide individual researchers and sequencing core laboratories with a cost-effective instrument that will deliver an accuracy level of 99.99 percent. The system uses the same highly-accurate ligation-based sequencing technology as the SOLiD 4 System, and coupled with a streamlined workflow, is engineered to deliver high-quality, sample-to-mapped data in as little as two days. Designed to generate up to 50 gigabases (Gb) of mappable sequence data per run, equivalent to up to 8 Gb per day, this powerful, yet intuitive system will support a breadth of next-generation sequencing applications that include, SNP calling and detection, targeted resequencing, whole transcriptome analysis and digital gene expression analysis.

The system also addresses the challenges related to capital and run costs facing scientists engaged in next-generation sequencing. The SOLiD PI System is anticipated to deliver a next-generation sequencer at a US list price of $230,000, with a cost per sample as low as $200.

“As sequencing becomes an ever more important tool for scientists to unlock the mechanisms of disease, it is critical that we provide a range of system solutions that meet the unique requirements of individual researchers,” said Kip Miller, President of the Genetic Systems Division for Life Technologies. “The SOLiD PI System builds on the superior data quality and accuracy of our SOLiD system chemistry, but delivers it in a more affordable format that will bring the power of next-generation sequencing to every laboratory.”

The SOLiD PI System is the latest addition to Life Technologies’ portfolio of sequencing solutions. The company recently announced the introduction of the SOLiD 4 System, which delivers unprecedented accuracy in next-generation sequencing. These offerings, along with the company’s gold-standard capillary electrophoresis (CE) instrumentation, demonstrate Life Technologies’ commitment to innovation across the research continuum, supporting sequencing analysis from discovery through validation and screening.

For more information on the SOliD PI System please visit www.appliedbiosystems.com/solidpi

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit us online at www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.